Recent advances in dyspnea

Chest

Volumn 147, Issue 1, 2015, Pages 232-241

  Mahler, Donald A ^a   O'Donnell, Denis E ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BOSENTAN; BRONCHODILATING AGENT; CORTICOSTEROID; MORPHINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NALOXONE; OPIATE; PIRFENIDONE; PLACEBO;

ACUPUNCTURE; ANXIETY; ARTICLE; ARTIFICIAL VENTILATION; BRAIN DEPTH STIMULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CINGULOTOMY; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG RESPONSE; DYSPNEA; EXERCISE; FIBROSING ALVEOLITIS; HUMAN; INSPIRATORY CAPACITY; LUNG EXAMINATION; LUNG VOLUME; PHASE 3 CLINICAL TRIAL (TOPIC); PUBLICATION; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION CONTROL; SURGICAL TECHNIQUE; LUNG; PATHOPHYSIOLOGY; PHYSIOLOGY;

DYSPNEA; EXERCISE; HUMANS; INSPIRATORY CAPACITY; LUNG;

EID: 84920748067     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0800     Document Type: Article

References (95)

1. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011; 37 (2): 264-272.
2. Guenette JA, Jensen D. Aging and sex differences. In: Mahler DA, O'Donnell DE, eds. Dyspnea: Mechanisms, Measurement, and Managment. London, England : CRC Press; 2014 : 25-37.
3. Hayen A, Herigstad M, Pattinson KT. Understanding dyspnea as a complex individual experience. Maturitas. 2013; 76 (1): 45-50.
4. Ward T, Scheid V, Tuffrey V. Women's mid-life health experiences in urban UK: an international comparison. Climacteric. 2010; 13 (3): 278-288.
5. Ingle L, Cleland JG, Clark AL. Body mass index is related to the perception of exertional breathlessness in patients presenting with dyspnoea of unknown origin. Int J Cardiol. 2012; 157 (2): 300-303.
6. Zutler M, Singer JP, Omachi TA, et al. Relationship of obesity with respiratory symptoms and decreased functional capacity in adults without established COPD. Prim Care Respir J. 2012; 21 (2): 194-201.
7. Jensen D, O'Donnell DE. Pregnancy/obesity. In: Mahler DA, O'Donnell DE, eds. Dyspnea: Mechanisms, Measurement, and Management. London, England : CRC Press; 2014 : 39-53.
8. O'Donnell DE, Ciavaglia CE, Neder JA. When obesity and chronic obstructive pulmonary disease collide. Physiological and clinical consequences. Ann Am Thorac Soc. 2014; 11 (4): 635-644.
9. Hanania NA, Müllerova H, Locantore NW, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011; 183 (5): 604-611.
10. Nguyen HQ, Fan VS, Herting J, et al. Patients with COPD with higher levels of anxiety are more physically active. Chest. 2013; 144 (1): 145-151.
11. Yohannes AM, Willgoss TG, Baldwin RC, Connolly MJ. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry. 2010; 25 (12): 1209-1221.
12. Atlantis E, Fahey P, Cochrane B, Smith S. Bidirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta-analysis. Chest. 2013; 144 (3): 766-777.
13. von Leupoldt A, Chan PY, Bradley MM, Lang PJ, Davenport PW. The impact of anxiety on the neural processing of respiratory sensations. Neuroimage. 2011; 55 (1): 247-252.
14. von Leupoldt A, Van den Bergh O, Davenport PW. Anxiety, depression, and panic. In: Mahler DA, O'Donnell DE, eds. Dyspnea: Mechanisms, Measurement, and Management. London, England : CRC Press; 2014 : 129-143.
15. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121 (5): 1434-1440.
16. Argulian E, Agarwal V, Bangalore S, et al. Meta-analysis of prognostic implications of dyspnea versus chest pain in patients referred for stress testing. Am J Cardiol. 2014; 113 (3): 559-564.
17. Berraho M. Dyspnea: a strong independent factor for long-term mortality in the elderly. J Nutr Health Aging. 2013; 17 (10): 908-912.
18. O'Donnell DE, Ora J, Webb KA, Laveneziana P, Jensen D. Mechanisms of activity-related dyspnea in pulmonary diseases. Respir Physiol Neurobiol. 2009; 167 (1): 116-132.
19. Mahler DA, O'Donnell DE. Dyspnea: mechanisms, measurement, and management. In: Mahler DA, O'Donnell DE, eds. Neurobiology of Dyspnea: An Overview. London, England : CRC Press; 2014 : 3-10
20. Parshall MB, Schwartzstein RM, Adams L, et al; American Thoracic Society Committee on Dyspnea. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012; 185 (4): 435-452.
21. Gifford AH, Mahler DA, Waterman LA, et al. Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD. COPD. 2011; 8 (3): 160-166.
22. Mahler DA, Murray JA, Waterman LA, et al. Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur Respir J. 2009; 33 (4): 771-777.
23. Mahler DA, Gifford AH, Waterman LA, et al. Effect of increased blood levels of b-endorphin on perception of breathlessness. Chest. 2013; 143 (5): 1378-1385.
24. Mahler DA, Gifford AH, Gilani A, et al. Antagonism of substance P and perception of breathlessness in patients with chronic obstructive pulmonary disease. Respir Physiol Neurobiol. 2014; 196 : 1-7.
25. Evans KC, Banzett RB. Dyspnea: mechanisms, measurement, and management. In: Mahler DA, O'Donnell DE, eds. Neuroimaging of Dyspnea. London, England : CRC Press; 2014 : 11-24.
26. Herigstad M, Hayen A, Wiech K, Pattinson KT. Dyspnoea and the brain. Respir Med. 2011; 105 (6): 809-817.
27. Ciavaglia CE, Guenette JA, Ora J, Webb KA, Neder JA, O'Donnell DE. Does exercise test modality influence dyspnoea perception in obese patients with COPD? Eur Respir J. 2014; 43 (6): 1621-1630.
28. Holm SM, Rodgers W, Haennel RG, et al. Effect of modality on cardiopulmonary exercise testing in male and female COPD patients. Respir Physiol Neurobiol. 2014; 192 : 30-38.
29. Guenette JA, Webb KA, O'Donnell DE. Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD? Eur Respir J. 2012; 40 (2): 322-329.
30. O'Donnell DE, Guenette JA, Maltais F, Webb KA. Decline of resting inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise. Chest. 2012; 141 (3): 753-762.
31. Laveneziana P, Webb KA, Ora J, Wadell K, O'Donnell DE. Evolution of dyspnea during exercise in chronic obstructive pulmonary disease: impact of critical volume constraints. Am J Respir Crit Care Med. 2011; 184 (12): 1367-1373.
32. O'Donnell DE, Webb KA, Mahler DA. Effect of bronchodilators and inhaled corticosteroids on dyspnea in chronic obstructive pulmonary disease. In: Mahler DA, O'Donnell DE, eds. Dyspnea: Mechanisms, Measurement, and Management. London, England : CRC Press; 2014 : 161-175.
33. Gagnon P, Bussières JS, Ribeiro F, et al. Influences of spinal anesthesia on exercise tolerance in patients with chronic obstructive pulmonary disease. A m J Respir Crit Care Med. 2012; 186 (7): 606-615.
34. Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax. 2010; 65 (1): 21-26.
35. Meek PM, Banzett R, Parshall MB, Gracely RH, Schwartzstein RM, Lansing R. Reliability and validity of the multidimensional dyspnea profile. C hest. 2012; 141 (6): 1546-1553.
36. Hareendran A, Klien Leidy NK. Measurement of dyspnea in clinical trials. In: Mahler DA, O'Donnell DE, eds. Dyspnea: Mechanisms, Measurement, and Management. London, England : CRC Press; 2014 : 111-127.
37. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187 (4): 347-365.
38. Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med. 2013; 1 (1): 43-50.
39. Agusti A, Edwards LD, Celli B, et al; ECLIPSE Investigators. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013; 42 (3): 636-646.
40. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. C an Respir J. 2007; 14 (suppl B): 5B - 32B.
41. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Prim Care Respir J. 2013; 22 (1): 117-121.
42. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007; 120 (5 Suppl): S94 - S138.
43. Blackwell TS, Tager AM, Borok Z, et al. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med. 2014; 189 (2): 214-222.
44. McLaughlin VV, Archer SL, Badesch DB, et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009; 53(17): 1573-1619.
45. Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62 (16): e147 - e239.
46. Beeh KM, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD. 2011; 8 (5): 340-345.
47. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012; 7 : 503-513.
48. Beeh KM, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014; 108 (4): 584-592.
49. Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med. 2011; 105 (4): 580-587.
50. Worth H, Förster K, Eriksson G, Nihlén U, Peterson S, Magnussen H. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med. 2010; 104 (10): 1450-1459.
51. O'Donnell DE, Casaburi R, Vincken W, et al; INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011; 105 (7): 1030-1036.
52. Cazzola M, MacNee W, Martinez FJ, et al; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008; 31 (2): 416-469.
53. Dahl R, Chung KF, Buhl R, et al; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65 (6): 473-479.
54. Kornmann O, Dahl R, Centanni S, et al; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011; 37 (2): 273-279.
55. Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B. Efficacy of indacaterol 75 μ g once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. COPD. 2012; 9 (6): 629-636.
56. Kinoshita M, Lee SH, Hang LW, et al; Indacaterol Asian COPD Study Investigators. Efficacy and safety of indacaterol 150 and 300 μ g in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology. 2012; 17 (2): 379-389.
57. Donohue JF, Fogarty C, Lötvall J, et al; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010; 182 (2): 155-162.
58. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF; ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012; 9 (2): 90-101.
59. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twicedaily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012; 40 (4): 830-836.
60. D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011; 12 : 156.
61. Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012; 40 (5): 1106-1114.
62. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013; 107 (10): 1538-1546.
63. Mahler DA, Decramer M, D'Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014; 43 (6): 1599-1609.
64. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014; 145 (5): 981-991.
65. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005; 2 (1): 99-103.
66. Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 m g; 100/25 m g) on lung function in COPD. Respir Med. 2013; 107 (4): 560-569.
67. Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 m g) improves lung function in COPD: a randomised trial. Respir Med. 2013; 107 (4): 550-559.
68. Swigris JJ, Fairclough D. Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest. 2012; 142 (2): 291-297.
69. Raghu G, King TE Jr, Behr J, et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J. 2010; 35 (1): 118-123.
70. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. A m J Respir Crit Care Med. 2011; 184 (1): 92-99.
71. King TE Jr, Bradford WZ, Castro-Bernardini S, et al; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370 (22): 2083-2092.
72. Wadell K, Webb KA, Preston ME, et al. Impact of pulmonary rehabilitation on the major dimensions of dyspnea in COPD. COPD. 2013; 10 (4): 425-435.
73. Mahler DA. Opioids for refractory dyspnea. E xpert Rev Respir Med. 2013; 7 (2): 123-134.
74. Mahler DA, Selecky PA, Harrod CG, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest. 2010; 137 (3): 674-691.
75. Marciniuk DD, Goodridge D, Hernandez P, et al; Canadian Thoracic Society COPD Committee Dyspnea Expert Working Group. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011; 18 (2): 69-78.
76. Banzett RB, Adams L, O'Donnell CR, Gilman SA, Lansing RW, Schwartzstein RM. Using laboratory models to test treatment: morphine reduces dyspnea and hypercapnic ventilatory response. Am J Respir Crit Care Med. 2011; 184 (8): 920-927.
77. Oxberry SG, Torgerson DJ, Bland JM, Clark AL, Cleland JG, Johnson MJ. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. Eur J Heart Fail. 2011; 13 (9): 1006-1012.
78. Oxberry SG, Bland JM, Clark AL, Cleland JG, Johnson MJ. Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough. J Palliat Med. 2013; 16 (3): 250-255.
79. Pinna MA, Bruera E, Moralo MJ, Correas MA and Vargas RM. A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer [published online ahead of print November 20, 2013]. Am J Hosp Palliat Care. doi:10.1177/1049909113513063.
80. Jensen D, Alsuhail A, Viola R, Dudgeon DJ, Webb KA, O'Donnell DE. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manage. 2012; 43 (4): 706-719.
81. Ben-Aharon I, Gaft er-Gvili A, Leibovici L, Stemmer SM. Interventions for alleviating cancer-related dyspnea: a systematic review and meta-analysis. Acta Oncol. 2012; 51 (8): 996-1008.
82. Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011; 42 (3): 388-399.
83. Johnson MJ, Bland JM, Oxberry SG, Abernethy AP, Currow DC. Opioids for chronic refractory breathlessness: patient predictors of beneficial response. Eur Respir J. 2013; 42 (3): 758-766.
84. Mahler DA. Other treatments for dyspnea. In: Mahler DA, O'Donnell DE, eds. Dyspnea: Mechanisms, Measurement, and Management. London, England : CRC Press; 2014 : 207-221.
85. Jones AY, Ngai SP, Hui-Chan CW, Yu HP. Acute effects of Acu-TENS on FEV1 and blood β-endorphin level in chronic obstructive pulmonary disease. Altern Ther Health Med. 2011; 17 (5): 8-13.
86. Suzuki M, Muro S, Ando Y, et al. A randomized, placebo-controlled trial of acupuncture in patients with chronic obstructive pulmonary disease (COPD): the COPD-acupuncture trial (CAT). Arch Intern Med. 2012; 172 (11): 878-886.
87. Viswanathan A, Harsh V, Pereira EA, Aziz TZ. Cingulotomy for medically refractory cancer pain. Neurosurg Focus. 2013; 35 (3): E1.
88. Pereira EA, Paranathala M, Hyam JA, Green AL and Aziz TZ. Anterior cingulotomy improves malignant mesothelioma pain and dyspnea. B r J Neurosurg. 2014; 28 (4): 471-474.
89. Ninane V, Geltner C, Bezzi M, et al. Multicentre European study for the treatment of advanced emphysema with bronchial valves. Eur Respir J. 2012; 39 (6): 1319-1325.
90. Sciurba FC, Ernst A, Herth FJ, et al; VENT Study Research Group. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med. 2010; 363 (13): 1233-1244.
91. Shah PL, Herth FJ. Current status of bronchoscopic lung volume reduction with endobronchial valves. Thorax. 2014; 69 (3): 280-286.
92. National Institutes of Health Clinical Center. Lung volume reduction coil treatment in patients with emphysema (RENEW) study. NCT01608490. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2012. http://clinicaltrials.gov/show/NCT01608490. Updated July 4, 2014.
93. Smith HS, Pilitsis JG. Neuromodulation and palliative medicine. Am J Hosp Palliat Care. 2014; 31 (2): 211-219.
94. Vieira PJ, Chiappa AM, Cipriano G Jr, Umpierre D, Arena R, Chiappa GR. Neuromuscular electrical stimulation improves clinical and physiological function in COPD patients. Respir Med. 2014; 108 (4): 609-620.
95. Porszasz J, Cao R, Morishige R, van Eykern LA, Stenzler A, Casaburi R. Physiologic effects of an ambulatory ventilation system in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 188 (3): 334-342.